Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Apr 19;61(4):756.
doi: 10.3390/medicina61040756.

The Impact of Coagulation Biomarkers on Survival Outcomes in Adult Glioblastoma

Rahmi Atıl Aksoy  1   2 , Timur Koca  1 , Yasemin Şengün  1   3 , Ece Atak  1 , Aylin Fidan Korcum  1
Affiliations

The Impact of Coagulation Biomarkers on Survival Outcomes in Adult Glioblastoma

Rahmi Atıl Aksoy et al. Medicina (Kaunas). .

Abstract

Background and Objectives: Glioblastoma presents a significant challenge in oncology due to its aggressive nature and poor prognosis, despite advancements in treatment. This study aims to comprehensively evaluate the prognostic significance of coagulation biomarkers, including the novel albumin/D-dimer ratio, in adult glioblastoma patients. Material and Methods: This retrospective study included 74 adult glioblastoma patients who underwent Stupp protocol treatment. Blood samples were collected before radiotherapy to measure biomarkers, including prothrombin time (PT), activated partial thromboplastin time (aPTT), albumin, D-dimer, and the albumin/D-dimer ratio. The prognostic significance of these biomarkers for progression-free survival (PFS) and overall survival (OS) was assessed using both univariate and multivariate Cox regression analyses. Results: The median follow-up time was 12.2 months (range, 1-77.4 months). Univariate analysis revealed that ECOG performance status (p = 0.001), D-dimer (p = 0.03), and albumin (p = 0.001) were significant prognostic factors for PFS. Multivariate analysis identified albumin (p = 0.02) as an independent prognostic biomarker for PFS. For OS, univariate analysis showed that age (p = 0.004), ECOG performance status (p = 0.001), tumor volume (p = 0.007), extent of resection (p = 0.01), radiotherapy dose (p = 0.001), D-dimer (p = 0.02), albumin (p = 0.001), albumin/D-dimer ratio (p = 0.02), and PT (p = 0.002) were significant prognostic factors. Multivariate analysis revealed age (p = 0.04), extent of resection (p = 0.02), and PT (p = 0.04) as independent prognostic factors for OS. Conclusions: Our findings highlight the prognostic significance of coagulation biomarkers, particularly PT, D-dimer, albumin, and the albumin/D-dimer ratio, in glioblastoma. These biomarkers may serve as valuable tools for prognostic assessment and personalized treatment strategies, warranting further exploration in larger prospective studies.

Keywords: D-dimer; albumin; coagulation; glioblastoma; prothrombin time; survival.

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no conflicts of interest.

Figures

Figure 1
Figure 1
Receiver Operating Characteristic (ROC) curve analysis evaluating laboratory parameters in adult glioblastoma. (a) D-dimer. (b) Albumin. (c) Albumin/D-dimer ratio. (d) Prothrombin Time.
Figure 2
Figure 2
Kaplan–Meier survival curves illustrating progression-free survival based on D-dimer levels (a) and prothrombin time (b).
Figure 3
Figure 3
Kaplan–Meier survival curves illustrating overall survival based on D-dimer levels (a) and prothrombin time (b).
See this image and copyright information in PMC

Similar articles

See all similar articles

References

    1. Ostrom Q.T., Gittleman H., Truitt G., Boscia A., Kruchko C., Barnholtz-Sloan J.S. CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2011–2015. Neuro Oncol. 2018;20((Suppl. 4)):iv1–iv86. doi: 10.1093/neuonc/noy131. Erratum in Neuro Oncol. 2018, 23, 508–522. https://doi.org/10.1093/neuonc/noy171 . - DOI - PMC - PubMed
    1. Stupp R., Mason W.P., van den Bent M.J., Weller M., Fisher B., Taphoorn M.J.B., Belanger K., Brandes A.A., Marosi C., Bogdahn U., et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N. Engl. J. Med. 2005;352:987–996. doi: 10.1056/NEJMoa043330. - DOI - PubMed
    1. Tan A.C., Ashley D.M., López G.Y., Malinzak M., Friedman H.S., Khasraw M. Management of glioblastoma: State of the art and future directions. CA Cancer J. Clin. 2020;70:299–312. doi: 10.3322/caac.21613. - DOI - PubMed
    1. Thakkar J.P., Dolecek T.A., Horbinski C., Ostrom Q.T., Lightner D.D., Barnholtz-Sloan J.S., Villano J.L. Epidemiologic and molecular prognostic review of glioblastoma. Cancer Epidemiol. Biomark. Prev. 2014;23:1985–1996. doi: 10.1158/1055-9965.EPI-14-0275. - DOI - PMC - PubMed
    1. Cho A., McKelvey K.J., Lee A., Hudson A.L. The intertwined fates of inflammation and coagulation in glioma. Mamm. Genome. 2018;29:806–816. doi: 10.1007/s00335-018-9761-8. - DOI - PubMed

MeSH terms

LinkOut - more resources